5,540 Shares in Dynavax Technologies Co. (NASDAQ:DVAX) Bought by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 5,540 shares of the biopharmaceutical company’s stock, valued at approximately $71,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. US Bancorp DE grew its position in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP bought a new position in Dynavax Technologies in the third quarter valued at about $45,000. GAMMA Investing LLC raised its stake in shares of Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Dynavax Technologies in the 3rd quarter valued at about $89,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $13.33 on Friday. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of 102.55 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.05. The business has a 50-day simple moving average of $12.81 and a two-hundred day simple moving average of $11.99.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05. The company had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%. On average, analysts expect that Dynavax Technologies Co. will post 0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday. StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Finally, William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research note on Friday.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.